Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
JBJS Case Connect ; 9(4): e0370, 2019 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-31644432

RESUMEN

CASE: An otherwise healthy 39-year-old man presented after a fall from 30 feet with a right transverse, transtectal acetabular fracture. The fracture was not reducible with an isolated anterior or posterior approach. A simultaneous combined approach was used in the lateral decubitus position. The fracture was appropriately reduced and stabilized. CONCLUSIONS: This combined approach with the patient in the lateral decubitus position was effective without requiring repositioning of the patient during surgery. This technique may be helpful for reduction of challenging transverse acetabular fractures.


Asunto(s)
Acetábulo/lesiones , Fijación Interna de Fracturas/métodos , Fracturas Óseas/cirugía , Reducción Abierta/métodos , Accidentes por Caídas , Acetábulo/diagnóstico por imagen , Adulto , Fracturas Óseas/diagnóstico por imagen , Humanos , Masculino , Tomografía Computarizada por Rayos X
2.
JAMA Facial Plast Surg ; 21(2): 110-117, 2019 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-30520953

RESUMEN

IMPORTANCE: Osseous craniofacial defects are currently reconstructed with bone grafting, rigid fixation, free tissue transfer, and/or recombinant human bone morphogenetic protein 2. Although these treatment options often have good outcomes, they are associated with substantial morbidity, and many patients are not candidates for free tissue transfer. OBJECTIVE: To assess whether polysaccharide-based scaffold (PS) constructs that are cross-linked with smoothened agonist (SAG), vascular endothelial growth factor (VEGF), and bone morphogenetic protein 6 (BMP-6) would substantially increase bone regeneration. DESIGN, SETTING, AND PARTICIPANTS: This animal model study was conducted at the University of Virginia School of Medicine Cui Laboratory from March 1, 2017, to June 30, 2017. Thirty-three 10-week-old female Lewis rats were acquired for the study. Bilateral nonsegmental critical-sized defects were created in the angle of rat mandibles. The defects were either left untreated or filled with 1 of the 9 PSs. The rats were killed after 8 weeks, and bone regeneration was evaluated using microcomputed tomographic imaging and mechanical testing. Analysis of variance testing was used to compare the treatment groups. MAIN OUTCOMES AND MEASURES: Blinded analysis and computer analysis of the microcomputed tomographic images were used to assess bone regeneration. RESULTS: In the 33 female Lewis rats, minimal healing was observed in the untreated mandibles. Addition of SAG was associated with increases in bone regeneration and bone density in all treatment groups, and maximum bone healing was seen in the group with BMP-6, VEGF, and SAG cross-linked to PS. For each of the 5 no scaffold group vs BMP-6, VEGF, and SAG cross-linked to PS group comparisons, mean defect bone regeneration was 4.14% (95% CI, 0.94%-7.33%) vs 66.19% (95% CI, 54.47%-77.90%); mean bone volume, 14.52 mm3 (95% CI, 13.07-15.97 mm3) vs 20.87 mm3 (95% CI, 14.73- 27.01 mm3); mean bone surface, 68.97 mm2 (95% CI, 60.08-77.85 mm2) vs 96.77 mm2 (95% CI, 76.11-117.43 mm2); mean ratio of bone volume to total volume, 0.11 (95% CI, 0.10-0.11) vs 0.15 (95% CI, 0.10-0.19); and mean connectivity density 0.03 (95% CI, 0.02-0.05) vs 0.32 (95% CI, 0.25-0.38). On mechanical testing, mandibles with untreated defects broke with less force than control mandibles in which no defect was made, although this force did not reach statistical significance. No significant difference in force to fracture was observed among the treatment groups. CONCLUSIONS AND RELEVANCE: In this rat model study, activation of the hedgehog signaling pathway using smoothened agonist was associated with increased craniofacial bone regeneration compared with growth factors alone, including US Food and Drug Administration-approved recombinant human bone morphogenetic protein 2. Pharmaceuticals that target this pathway may offer a new reconstructive option for bony craniofacial defects as well as nonunion and delayed healing fractures. LEVEL OF EVIDENCE: NA.


Asunto(s)
Regeneración Ósea/fisiología , Proteínas Hedgehog/metabolismo , Mandíbula/cirugía , Animales , Densidad Ósea , Proteína Morfogenética Ósea 2/farmacología , Proteína Morfogenética Ósea 6/farmacología , Sustitutos de Huesos/farmacología , Trasplante Óseo , Femenino , Modelos Animales , Ratas , Ratas Endogámicas Lew , Transducción de Señal , Andamios del Tejido , Factor A de Crecimiento Endotelial Vascular/farmacología , Cicatrización de Heridas , Microtomografía por Rayos X
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...